NEO 📈 NeoGenomics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US64049M2098
NEO: Cancer, Testing, Laboratory, Services, Diagnostics, Molecular, Genetics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida. Web URL: https://www.neogenomics.com
Additional Sources for NEO Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NEO Stock Overview
Market Cap in USD | 2,276m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 1999-11-02 |
NEO Stock Ratings
Growth 5y | -45.2% |
Fundamental | -26.8% |
Dividend | - |
Rel. Strength Industry | -386 |
Analysts | 4.31/5 |
Fair Price Momentum | 13.93 USD |
Fair Price DCF | - |
NEO Dividends
No Dividends PaidNEO Growth Ratios
Growth Correlation 3m | 76.8% |
Growth Correlation 12m | 8.9% |
Growth Correlation 5y | -62.6% |
CAGR 5y | -11.25% |
CAGR/Mean DD 5y | -0.22 |
Sharpe Ratio 12m | -0.30 |
Alpha | -55.66 |
Beta | 1.41 |
Volatility | 47.76% |
Current Volume | 3306k |
Average Volume 20d | 765.3k |
What is the price of NEO stocks?
As of December 21, 2024, the stock is trading at USD 16.41 with a total of 3,306,028 shares traded.
Over the past week, the price has changed by -7.45%, over one month by +6.84%, over three months by +0.80% and over the past year by -14.71%.
As of December 21, 2024, the stock is trading at USD 16.41 with a total of 3,306,028 shares traded.
Over the past week, the price has changed by -7.45%, over one month by +6.84%, over three months by +0.80% and over the past year by -14.71%.
Is NeoGenomics a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, NeoGenomics (NASDAQ:NEO) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -26.81 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NEO as of December 2024 is 13.93. This means that NEO is currently overvalued and has a potential downside of -15.11%.
Probably not. Based on ValueRay Fundamental Analyses, NeoGenomics (NASDAQ:NEO) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -26.81 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NEO as of December 2024 is 13.93. This means that NEO is currently overvalued and has a potential downside of -15.11%.
Is NEO a buy, sell or hold?
NeoGenomics has received a consensus analysts rating of 4.31. Therefor, it is recommend to buy NEO.
NeoGenomics has received a consensus analysts rating of 4.31. Therefor, it is recommend to buy NEO.
- Strong Buy: 7
- Buy: 3
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecast for NEO stock price target?
According to ValueRays Forecast Model, NEO NeoGenomics will be worth about 15.4 in December 2025. The stock is currently trading at 16.41. This means that the stock has a potential downside of -5.91%.
According to ValueRays Forecast Model, NEO NeoGenomics will be worth about 15.4 in December 2025. The stock is currently trading at 16.41. This means that the stock has a potential downside of -5.91%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 20.9 | 27.4% |
Analysts Target Price | 20.4 | 24.1% |
ValueRay Target Price | 15.4 | -5.9% |